Drug Interactions between dofetilide and Nexium
This report displays the potential drug interactions for the following 2 drugs:
- dofetilide
- Nexium (esomeprazole)
Interactions between your drugs
No interactions were found between dofetilide and Nexium. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
dofetilide
A total of 423 drugs are known to interact with dofetilide.
- Dofetilide is in the drug class group III antiarrhythmics.
- Dofetilide is used to treat Arrhythmia.
Nexium
A total of 216 drugs are known to interact with Nexium.
- Nexium is in the drug class proton pump inhibitors.
- Nexium is used to treat the following conditions:
Drug and food interactions
esomeprazole food
Applies to: Nexium (esomeprazole)
ADJUST DOSING INTERVAL: Food may interfere with the absorption of esomeprazole. The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.
MANAGEMENT: Esomeprazole should be taken at least one hour before meals. When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.
References (2)
- (2001) "Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
dofetilide food
Applies to: dofetilide
In vitro data suggest that grapefruit juice may inhibit the CYP450 3A4 first-pass metabolism of dofetilide. Decreased first-pass metabolism may increase dofetilide concentrations and increase the risk of QT interval prolongation and arrhythmias. The clinical significance is unknown, since dofetilide has a high oral bioavailability and a low affinity for CYP450 3A4. The manufacturer recommends caution.
References (1)
- (2001) "Product Information. Tikosyn (dofetilide)." Pfizer U.S. Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.